Treatment of Bacterial Meningitis in Patients with a Cerebrospinal Fluid Shunt
Bacterial meningitis occurring in a patient with a cerebrospinal fluid (CSF) shunt is a distinct clinical scenario. The shunt introduces specific considerations that shape the treatment approach and agent selection compared with meningitis in patients without a shunt.
Clinical Scenario
This protocol addresses patients with a cerebrospinal fluid shunt who develop bacterial meningitis. Identifying the shunt as a contributing factor is essential for selecting the appropriate management strategy.
Treatment Approach
Management involves a corticosteroid — used in eligible patients — administered before or at the time of intravenous antibiotic therapy, with an alternative antibiotic combination available based on clinical context.
The complete regimen, specific agents, sequencing, and contingencies are detailed in the full protocol.
Clinical Goal
The primary target is clinical improvement within 48 hours of initiating appropriate treatment. Absence of expected improvement within that window warrants further evaluation.
References
- Patients with cerebrospinal fluid shunt
- Vancomycin plus cefepime
- Alternative: meropenem plus vancomycin
- Because the etiology is not known at presentation, dexamethasone should be given before or at the time of initial antibiotics while awaiting the final culture results in all patients older than six weeks with suspected bacterial meningitis.
- Dexamethasone can be discontinued after four days or earlier if the pathogen is not H. influenzae or S. pneumoniae, or if CSF findings are more consistent with aseptic meningitis.
- Repeat LP is generally not needed but should be considered to evaluate CSF parameters in persons who are not clinically improving after 48 hours of appropriate treatment.
View source ↗